Federal grant · cooperative agreement (b)
Ideas Lab: Usprd: Ai-designed Enzymes Using Non-natural Cofactors for the Production of Bio-based Acrylates -ai-designed Enzymes Using Non-natural Cofactors for the Production of Bio-based Acrylates the Project Aims to Transform the Production of Molecules Known as Acrylates With Artificial Intelligence (ai)-driven Biotechnology. Acrylates Are Expensive Components of Paints, Plexiglas?, and Super-absorbent Materials. by Using Engineered Enzymes and Innovative, Low-cost Chemicals, the Process Will Convert Affordable Plant Material Into These High-value Products Instead. the Team of Experts From Academia and Industry Will Test This Technology at Pilot Scales, Demonstrating Its Potential to Strengthen the U.s. Bioeconomy. the Project Will Also Train a New Workforce in Protein Design and Synthetic Biology. This Project Leverages Artificial Intelligence and Advanced Protein Engineering to Develop a Scalable, Cost-effective, and Cell-free Biocatalytic Process for Producing Methylene Butyrolactone (MBL), a Bio-based Acrylate Monomer. the Work Begins With Mining and Redesigning Natural Enzymes to Catalyze the Conversion of Itaconate to MBL Using Machine Learning-guided Frameworks and High-throughput Design-build-test-learn Cycles. Enzymes Will Be Further Engineered to Utilize a Non-natural Cofactor, Which Provides Enhanced Stability, Cost Efficiency, and Suitability for Industrial Conditions While Overcoming Traditional Biochemical Limitations. Subsequent Phases Involve Strain Engineering for Enzyme Production at Titers Exceeding 1 G/L in E. Coli and Demonstrating the Complete Process in 1-5L Bioreactors. by Coupling Enzymes With Chemical Conversion Processes, the Project Integrates Enzyme Performance, Cofactor Recycling, and Chemical Efficiency to Achieve Over 90% Yield at Industrial Scales. Beyond Enabling Cost-competitive MBL Production, This Project Overcomes Key Limitations of Natural Cofactor-dependent Enzymes, Advancing Cell-free Biocatalysis and Its Broader Applications in Synthetic Pathways. the Resulting Platform Will Drive Innovation Across the Bioeconomy, Transforming Industrial Biotechnology Through Enhanced Scalability and Efficiency. This Award Reflects NSF'S Statutory Mission and Has Been Deemed Worthy of Support Through Evaluation Using the Foundation's Intellectual Merit and Broader Impacts Review Criteria.- Subawards Are Planned for This Award.
Committed
$2.2 Million
Paid out
$1.9M
83%
Committed, not yet paid
$378.0K
17%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.